• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Amendment: SEC Form SCHEDULE 13G/A filed by SCYNEXIS Inc.

    10/7/25 11:11:24 AM ET
    $SCYX
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $SCYX alert in real time by email



    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549


    SCHEDULE 13G


    UNDER THE SECURITIES EXCHANGE ACT OF 1934
    (Amendment No. 15)


    SCYNEXIS INC

    (Name of Issuer)


    COMMON STOCK

    (Title of Class of Securities)


    811292200

    (CUSIP Number)


    09/30/2025

    (Date of Event Which Requires Filing of this Statement)


    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
    Checkbox checked   Rule 13d-1(b)
    Checkbox not checked   Rule 13d-1(c)
    Checkbox not checked   Rule 13d-1(d)






    SCHEDULE 13G

    CUSIP No.
    811292200


    1Names of Reporting Persons

    Federated Hermes, Inc.
    2Check the appropriate box if a member of a Group (see instructions)

    Checkbox not checked  (a)
    Checkbox not checked  (b)
    3Sec Use Only
    4Citizenship or Place of Organization

    PENNSYLVANIA
    Number of Shares Beneficially Owned by Each Reporting Person With:
    5Sole Voting Power

    5,116,598.00
    6Shared Voting Power

    0.00
    7Sole Dispositive Power

    5,116,598.00
    8Shared Dispositive Power

    0.00
    9Aggregate Amount Beneficially Owned by Each Reporting Person

    5,116,598.00
    10Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

    Checkbox not checked
    11Percent of class represented by amount in row (9)

    11.26 %
    12Type of Reporting Person (See Instructions)

    HC


    SCHEDULE 13G

    CUSIP No.
    811292200


    1Names of Reporting Persons

    Voting Shares Irrevocable Trust
    2Check the appropriate box if a member of a Group (see instructions)

    Checkbox not checked  (a)
    Checkbox not checked  (b)
    3Sec Use Only
    4Citizenship or Place of Organization

    PENNSYLVANIA
    Number of Shares Beneficially Owned by Each Reporting Person With:
    5Sole Voting Power

    5,116,598.00
    6Shared Voting Power

    0.00
    7Sole Dispositive Power

    5,116,598.00
    8Shared Dispositive Power

    0.00
    9Aggregate Amount Beneficially Owned by Each Reporting Person

    5,116,598.00
    10Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

    Checkbox not checked
    11Percent of class represented by amount in row (9)

    11.26 %
    12Type of Reporting Person (See Instructions)

    OO


    SCHEDULE 13G

    CUSIP No.
    811292200


    1Names of Reporting Persons

    Thomas R. Donahue
    2Check the appropriate box if a member of a Group (see instructions)

    Checkbox not checked  (a)
    Checkbox not checked  (b)
    3Sec Use Only
    4Citizenship or Place of Organization

    UNITED STATES
    Number of Shares Beneficially Owned by Each Reporting Person With:
    5Sole Voting Power

    0.00
    6Shared Voting Power

    5,116,598.00
    7Sole Dispositive Power

    0.00
    8Shared Dispositive Power

    5,116,598.00
    9Aggregate Amount Beneficially Owned by Each Reporting Person

    5,116,598.00
    10Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

    Checkbox not checked
    11Percent of class represented by amount in row (9)

    11.26 %
    12Type of Reporting Person (See Instructions)

    IN


    SCHEDULE 13G

    CUSIP No.
    811292200


    1Names of Reporting Persons

    Ann C. Donahue
    2Check the appropriate box if a member of a Group (see instructions)

    Checkbox not checked  (a)
    Checkbox not checked  (b)
    3Sec Use Only
    4Citizenship or Place of Organization

    UNITED STATES
    Number of Shares Beneficially Owned by Each Reporting Person With:
    5Sole Voting Power

    0.00
    6Shared Voting Power

    5,116,598.00
    7Sole Dispositive Power

    0.00
    8Shared Dispositive Power

    5,116,598.00
    9Aggregate Amount Beneficially Owned by Each Reporting Person

    5,116,598.00
    10Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

    Checkbox not checked
    11Percent of class represented by amount in row (9)

    11.26 %
    12Type of Reporting Person (See Instructions)

    IN


    SCHEDULE 13G

    CUSIP No.
    811292200


    1Names of Reporting Persons

    J. Christopher Donahue
    2Check the appropriate box if a member of a Group (see instructions)

    Checkbox not checked  (a)
    Checkbox not checked  (b)
    3Sec Use Only
    4Citizenship or Place of Organization

    UNITED STATES
    Number of Shares Beneficially Owned by Each Reporting Person With:
    5Sole Voting Power

    0.00
    6Shared Voting Power

    5,116,598.00
    7Sole Dispositive Power

    0.00
    8Shared Dispositive Power

    5,116,598.00
    9Aggregate Amount Beneficially Owned by Each Reporting Person

    5,116,598.00
    10Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

    Checkbox not checked
    11Percent of class represented by amount in row (9)

    11.26 %
    12Type of Reporting Person (See Instructions)

    IN


    SCHEDULE 13G

    Item 1. 
    (a)Name of issuer:

    SCYNEXIS INC
    (b)Address of issuer's principal executive offices:

    1 Evertrust Plaza, 13th Floor, Jersey City, NJ 07302-6548
    Item 2. 
    (a)Name of person filing:

    Federated Hermes, Inc.
    (b)Address or principal business office or, if none, residence:

    1001 Liberty Avenue, Pittsburgh, PA 15222-3779
    (c)Citizenship:

    Pennsylvania
    (d)Title of class of securities:

    COMMON STOCK
    (e)CUSIP No.:

    811292200
    Item 3.If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:
    (a)Checkbox not checked   Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);
    (b)Checkbox not checked   Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);
    (c)Checkbox not checked   Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);
    (d)Checkbox not checked   Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
    (e)Checkbox not checked   An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);
    (f)Checkbox not checked   An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);
    (g)Checkbox checked   A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);
    (h)Checkbox not checked   A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
    (i)Checkbox not checked   A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
    (j)Checkbox not checked   A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J). If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J),
           please specify the type of institution:
    (k)Checkbox not checked   Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K).
     
    Item 4.Ownership
    (a)Amount beneficially owned:

    5,116,598
    (b)Percent of class:

    11.26  %
    (c)Number of shares as to which the person has:
     (i) Sole power to vote or to direct the vote:

    5,116,598

     (ii) Shared power to vote or to direct the vote:

    0

     (iii) Sole power to dispose or to direct the disposition of:

    5,116,598

     (iv) Shared power to dispose or to direct the disposition of:

    0

    Item 5.Ownership of 5 Percent or Less of a Class.
     
    Item 6.Ownership of more than 5 Percent on Behalf of Another Person.
     
    Not Applicable
    Item 7.Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.
     
    If a parent holding company has filed this schedule, pursuant to Rule 13d-1(b)(ii)(G), so indicate under Item 3(g) and attach an exhibit stating the identity and the Item 3 classification of the relevant subsidiary. If a parent holding company has filed this schedule pursuant to Rule 13d-1(c) or Rule 13d-1(d), attach an exhibit stating the identification of the relevant subsidiary.


    See Exhibit "1" Attached
    Item 8.Identification and Classification of Members of the Group.
     
    Not Applicable
    Item 9.Notice of Dissolution of Group.
     
    Not Applicable

    Item 10.Certifications:
     
    By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under ?? 240.14a-11. By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under ?? 240.14a-11.

        SIGNATURE 
     
    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

     
    Federated Hermes, Inc.
     
    Signature:/s/J. Christopher Donahue
    Name/Title:J. Christopher Donahue, as President of Federated Hermes, Inc.
    Date:10/07/2025
     
    Voting Shares Irrevocable Trust
     
    Signature:/s/Thomas R. Donahue
    Name/Title:Thomas R. Donahue, as Trustee of Voting Shares Irrevocable Trust
    Date:10/07/2025
     
    Signature:/s/Ann C. Donahue
    Name/Title:Ann C. Donahue, as Trustee of Voting Shares Irrevocable Trust
    Date:10/07/2025
     
    Signature:/s/J. Christopher Donahue
    Name/Title:J. Christopher Donahue, as Trustee of Voting Shares Irrevocable Trust
    Date:10/07/2025
     
    Thomas R. Donahue
     
    Signature:/s/Thomas R. Donahue
    Name/Title:Thomas R. Donahue
    Date:10/07/2025
     
    Ann C. Donahue
     
    Signature:/s/Ann C. Donahue
    Name/Title:Ann C. Donahue
    Date:10/07/2025
     
    J. Christopher Donahue
     
    Signature:/s/J. Christopher Donahue
    Name/Title:J. Christopher Donahue
    Date:10/07/2025

    Comments accompanying signature:  SEE EXHIBITS 2 AND 3 ATTACHED Exhibit Information EXHIBIT 1 ITEM 3 CLASSIFICATION OF REPORTING PERSON EXHIBIT 2 AGREEMENT FOR JOINT FILING OF SCHEDULE 13G EXHIBIT 3 POWER OF ATTORNEY
    Get the next $SCYX alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $SCYX

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $SCYX
    SEC Filings

    View All

    Amendment: SEC Form SCHEDULE 13G/A filed by SCYNEXIS Inc.

    SCHEDULE 13G/A - SCYNEXIS INC (0001178253) (Subject)

    1/8/26 8:19:28 AM ET
    $SCYX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SCHEDULE 13G/A filed by SCYNEXIS Inc.

    SCHEDULE 13G/A - SCYNEXIS INC (0001178253) (Subject)

    11/14/25 2:27:47 PM ET
    $SCYX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SCHEDULE 13G/A filed by SCYNEXIS Inc.

    SCHEDULE 13G/A - SCYNEXIS INC (0001178253) (Subject)

    11/12/25 1:09:48 PM ET
    $SCYX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $SCYX
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Chief Financial Officer Macleod Ivor was granted 129,833 shares, increasing direct ownership by 48% to 398,529 units (SEC Form 4)

    4 - SCYNEXIS INC (0001178253) (Issuer)

    2/2/26 4:03:14 PM ET
    $SCYX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Chief Legal Officer Sukenick Scott was granted 129,833 shares, increasing direct ownership by 29% to 574,539 units (SEC Form 4)

    4 - SCYNEXIS INC (0001178253) (Issuer)

    2/2/26 4:02:11 PM ET
    $SCYX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Chief Executive Officer Angulo Gonzalez David was granted 391,333 shares, increasing direct ownership by 46% to 1,244,431 units (SEC Form 4)

    4 - SCYNEXIS INC (0001178253) (Issuer)

    2/2/26 4:01:08 PM ET
    $SCYX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $SCYX
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Aegis Capital reiterated coverage on SCYNEXIS with a new price target

    Aegis Capital reiterated coverage of SCYNEXIS with a rating of Buy and set a new price target of $35.00 from $40.00 previously

    6/7/21 9:58:05 AM ET
    $SCYX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Aegis Capital reiterated coverage on SCYNEXIS with a new price target

    Aegis Capital reiterated coverage of SCYNEXIS with a rating of Buy and set a new price target of $40.00 from $45.00 previously

    4/12/21 12:54:40 PM ET
    $SCYX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Maxim Group reiterated coverage on SCYNEXIS with a new price target

    Maxim Group reiterated coverage of SCYNEXIS with a rating of Buy and set a new price target of $22.00 from $17.00 previously

    2/17/21 2:23:39 PM ET
    $SCYX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $SCYX
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    SCYNEXIS Announces Presentations Highlighting the Potent Antifungal Activity of its Second-Generation Fungerp, SCY-247 Against Drug-Resistant Fungi, at the Inaugural Interdisciplinary Meeting on Antimicrobial Resistance and Innovation (IMARI)

    JERSEY CITY, N.J., Jan. 28, 2026 (GLOBE NEWSWIRE) -- SCYNEXIS, Inc. (NASDAQ:SCYX), a biotechnology company pioneering innovative medicines to overcome and prevent difficult-to-treat and drug-resistant infections, today announced upcoming presentations highlighting data on the Company's second-generation fungerp drug candidate, SCY-247, at the inaugural Interdisciplinary Meeting on Antimicrobial Resistance and Innovation (IMARI), which is taking place from January 28 to 30, 2026, in Las Vegas, Nevada. "We are pleased to participate in this important inaugural multidisciplinary meeting focused on addressing the significant threat of antimicrobial resistance," said David Angulo, M.D., Presi

    1/28/26 8:00:00 AM ET
    $SCYX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SCYNEXIS Receives FDA Qualified Infectious Disease Product (QIDP) and Fast Track Designations for SCY-247

    The QIDP designation will ensure at least 10 years of market exclusivity for SCY-247 following approval Recent articles highlight the growing threat from a rapidly spreading, multi-drug resistant, Candida auris fungal infection JERSEY CITY, N.J., Jan. 21, 2026 (GLOBE NEWSWIRE) -- SCYNEXIS, Inc. (NASDAQ:SCYX), a biotechnology company pioneering innovative medicines to overcome and prevent difficult-to-treat and drug-resistant infections, today announced that the U.S. Food and Drug Administration ("FDA") has granted the Company Qualified Infectious Disease Product (QIDP) and Fast Track Designations for its second-generation triterpenoid antifungal therapy, SCY-247. "Receiving FDA's QIDP

    1/21/26 8:00:00 AM ET
    $SCYX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SCYNEXIS Granted 180-Day Extension by Nasdaq to Regain Compliance with Minimum Bid Price Requirement

    JERSEY CITY, N.J., Dec. 22, 2025 (GLOBE NEWSWIRE) -- SCYNEXIS, Inc. (NASDAQ:SCYX), a biotechnology company pioneering innovative medicines to overcome and prevent difficult-to-treat and drug-resistant infections, today announced that it has received an additional 180-calendar-day extension from the Nasdaq Stock Market ("Nasdaq") to regain compliance with the minimum bid price requirement, as outlined in Nasdaq Listing Rule 5550(a)(2). The Company now has until June 15, 2026, to meet the requirement for its shares of common stock to maintain a closing bid price of at least $1.00 per share for a minimum of ten consecutive business days. Nasdaq granted the extension after determining that SC

    12/22/25 8:00:00 AM ET
    $SCYX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $SCYX
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Chief Executive Officer Angulo Gonzalez David bought $27,400 worth of shares (20,000 units at $1.37), increasing direct ownership by 4% to 507,871 units (SEC Form 4)

    4 - SCYNEXIS INC (0001178253) (Issuer)

    9/16/24 8:00:27 AM ET
    $SCYX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $SCYX
    FDA approvals

    Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

    View All

    FDA Approval for BREXAFEMME issued to SCYNEXIS, INC

    Submission status for SCYNEXIS, INC's drug BREXAFEMME (ORIG-1) with active ingredient IBREXAFUNGERP has changed to 'Approval' on 06/01/2021. Application Category: NDA, Application Number: 214900, Application Classification: Type 1 - New Molecular Entity

    6/2/21 11:20:46 AM ET
    $SCYX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    FDA Approval for BREXAFEMME issued to SCYNEXIS, INC

    Submission status for SCYNEXIS, INC's drug BREXAFEMME (SUPPL-1) with active ingredient IBREXAFUNGERP has changed to 'Approval' on 06/01/2021. Application Category: NDA, Application Number: 214900, Application Classification: Type 1 - New Molecular Entity

    6/2/21 9:57:42 AM ET
    $SCYX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $SCYX
    Leadership Updates

    Live Leadership Updates

    View All

    AUROBAC THERAPEUTICS welcomes two new independent members to its Board: Manos Perros, as Chairman, and Marco Taglietti

    Lyon - France, July 24, 2023 (GLOBE NEWSWIRE) -- AUROBAC THERAPEUTICS WELCOMES TWO NEW INDEPENDENT MEMBERS TO ITS BOARD: MANOS PERROS, AS CHAIRMAN, AND MARCO TAGLIETTI Dr Manos Perros and Dr Marco Taglietti are appointed new Independent Members of the Board of AUROBAC THERAPEUTICSDr Perros becomes Chairman of the Board These new appointments bring extensive US and international experience in company leadership and development of anti-infectives from R&D to commercialization Lyon (France), Thursday July 24, 2023 AUROBAC THERAPEUTICS SAS, a biopharmaceutical company developing the next generation of products to fight antimicrobial resistance (AMR), is delighted to announce th

    7/24/23 8:00:00 AM ET
    $SCYX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SCYNEXIS Reports First Quarter 2021 Financial Results and Provides Corporate Update

    Secured non-dilutive funding of approximately $35 million thus far in 2021, including licensing payments from Hansoh Pharma, the first tranche from a term loan agreement with Hercules and Silicon Valley Bank, and the monetization of the 2020 New Jersey NOLsAppointed Christine Coyne as Chief Commercial Officer to lead the launch of ibrexafungerp (Brexafemme®) for the treatment of vaginal yeast infections, following expected approval by June 1st Began dosing patients in a Phase 1 trial of the IV formulation of ibrexafungerpFurther strengthened balance sheet and projected cash runway into 2023 JERSEY CITY, N.J., May 17, 2021 (GLOBE NEWSWIRE) -- SCYNEXIS, Inc. (NASDAQ:SCYX), a biotechnology c

    5/17/21 8:30:00 AM ET
    $SCYX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SCYNEXIS Appoints Accomplished Commercial Executive Christine Coyne as Chief Commercial Officer to Lead the Brexafemme® Launch

    Strengthening the management team with deep anti-infective commercial expertise across hospital and community settings ahead of anticipated approval of Brexafemme (ibrexafungerp) in June 2021 and H2:2021 launch JERSEY CITY, N.J., May 11, 2021 (GLOBE NEWSWIRE) -- SCYNEXIS, Inc. (NASDAQ:SCYX), a biotechnology company pioneering innovative medicines to overcome and prevent difficult-to-treat and drug-resistant infections, today announced the appointment of Christine Coyne as Chief Commercial Officer, effective May 10, 2021. Ms. Coyne will play a significant role in the anticipated U.S. launch and commercialization of Brexafemme, the expected trade name for ibrexafungerp, an oral antifungal p

    5/11/21 8:30:00 AM ET
    $SCYX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $SCYX
    Financials

    Live finance-specific insights

    View All

    GSK and SCYNEXIS Announce an Exclusive Agreement to Commercialise and Further Develop Brexafemme (ibrexafungerp), a Novel, First-in-Class Medicine to Treat Fungal Infection

    Brexafemme complements GSK's industry-leading infectious disease portfolio with an FDA approved treatment for vulvovaginal candidiasisSCYNEXIS will receive an upfront payment of $90 million with future performance-based milestone payments and tiered royaltiesSCYNEXIS retains rights to all other assets derived from enfumafungin, with GSK having a right of first negotiation to these pre-clinical and discovery stage assetsSCYNEXIS to host an investor call and webcast at 8:30 a.m. EDT today LONDON and JERSEY CITY, N.J., March 30, 2023 (GLOBE NEWSWIRE) -- GSK plc (NYSE:GSK) and SCYNEXIS, Inc. (NASDAQ:SCYX), today announced they have entered into an exclusive licence agreement for Brexafemme (i

    3/30/23 7:05:00 AM ET
    $GSK
    $SCYX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SCYNEXIS Reports Third Quarter 2022 Financial Results and Provides Corporate Update

    SCYNEXIS recently announced new strategic direction to refocus its resources on the clinical development of ibrexafungerp for severe, hospital-based indications.Ivor Macleod, a 30-year biopharma veteran, joined SCYNEXIS as Chief Financial Officer.Marco Taglietti, M.D., to retire as President and Chief Executive Officer of SCYNEXIS and step down from the Board of Directors on December 31, 2022. David Angulo, M.D., Chief Medical Officer of SCYNEXIS will become President and Chief Executive Officer and join the Board effective January 1, 2023.BREXAFEMME® (ibrexafungerp tablets) prescriptions continued to grow in Q3 2022, increasing 13% over Q2 2022, generating net revenues of $1.6 million in Q3

    11/9/22 7:00:00 AM ET
    $SCYX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SCYNEXIS to Report Third Quarter 2022 Financial Results and Provide a Corporate Update on November 9

    JERSEY CITY, N.J., Nov. 01, 2022 (GLOBE NEWSWIRE) -- SCYNEXIS, Inc. (NASDAQ:SCYX), a biotechnology company pioneering innovative medicines to overcome and prevent difficult-to-treat and drug-resistant infections, today announced it will host a conference call and live webcast at 8:30 a.m. EDT on Wednesday, November 9, 2022, to provide a corporate update and discuss the Company's financial results for the third quarter ended September 30, 2022. Conference call and webcast details: Investors (domestic): (844) 826-3033Investors (international): (412) 317-5185Webcast:  LinkConference ID: 10172836 A live audio webcast can be accessed by visiting the Investor Relations section of the Company'

    11/1/22 8:30:00 AM ET
    $SCYX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $SCYX
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by SCYNEXIS Inc.

    SC 13G/A - SCYNEXIS INC (0001178253) (Subject)

    11/14/24 7:07:26 PM ET
    $SCYX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13G/A filed by SCYNEXIS Inc.

    SC 13G/A - SCYNEXIS INC (0001178253) (Subject)

    11/6/24 8:56:32 AM ET
    $SCYX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13G/A filed by SCYNEXIS Inc.

    SC 13G/A - SCYNEXIS INC (0001178253) (Subject)

    10/7/24 1:38:20 PM ET
    $SCYX
    Biotechnology: Pharmaceutical Preparations
    Health Care